Home
News
Screeners
Insights
Parnax Lab
135.
00
-2.23
(-1.63%)
Market Cap
₹155.70 Cr
PE Ratio
17.25
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-1.63%
1M
0.00%
6M
0.00%
1Y
0.00%
5Y
0.00%
View Company Insights
Latest news about Parnax Lab
Parnax Lab approves revised directors report for FY26
8 days ago
Board approved revised directors report for FY26. Secretarial audit report was also taken on record. Meeting held on August 26, 2026. Disclosure made under SEBI Regulation 30.
Parnax Lab sets record date for 44th AGM on September 22
8 days ago
Parnax Lab promoters Mihir, Prakash Shah acquire stakes via inter-se gift
Aug 14, 2026
Parnax Lab seeks approval for director re-appointment
Jul 09, 2026
Parnax Lab promoter acquires 3.15% stake via inter-se gift transfer
Jun 27, 2026
More news about Parnax Lab
28
May 26
Parnax Lab reports FY26 net profit of ₹1,177.68 lakh
Parnax Lab Limited reported a consolidated net profit of ₹1,177.68 lakh for FY26, up from ₹1,151.90 lakh in FY25, with total revenue rising to ₹25,232.56 lakh. The board approved the audited financial results and the re-appointment of Mr. Yogesh K. Varia as an Independent Director.
20
May 26
Parnax Lab board meets May 28 to consider Q4, FY26 results
Parnax Lab Limited will hold a board meeting on May 28, 2026, to approve audited financial results for Q4 and FY26. The trading window is closed from April 1, 2026, and will reopen 48 hours post-results.
08
Apr 26
Parnax Lab Ltd. Submits Quarterly Compliance Certificate for Q4 FY26 to BSE
Parnax Lab Ltd. filed its Q4 FY26 compliance certificate with BSE on April 8, 2026, confirming no dematerialization requests were received during the quarter ended March 31, 2026. The filing, made under SEBI Regulation 74(5), was verified by registrar MUFG Intime India Private Limited and signed by Company Secretary Preet Kukreja, demonstrating adherence to mandatory quarterly compliance requirements.
15
Feb 26
Parnax Lab Limited Reports Strong Q3FY26 Results with 56.45% Revenue Growth
Parnax Lab Limited announced robust Q3FY26 financial results with consolidated revenue from operations reaching ₹6,294.15 lakhs, marking a 56.45% year-on-year growth. The company's consolidated net profit surged 124.29% to ₹271.47 lakhs, while standalone operations showed even stronger growth with revenue increasing 174.58% to ₹270.82 lakhs and net profit jumping 349.43% to ₹70.91 lakhs.
Parnax Lab
135.
00
-
2.
23
(-
1.
63
%)
1 Year Returns:
0.00%
Industry Peers
Sun Pharmaceutical
1,916.00
(-
0.
81
%)
Divis Laboratories
9,250.00
(+
0.
33
%)
Torrent Pharmaceuticals
4,905.50
(-
2.
12
%)
Zydus Life Science
1,143.00
(-
0.
97
%)
Cipla
1,394.70
(-
1.
28
%)
Laurus Labs
1,868.50
(+
0.
24
%)
Mankind Pharma
2,368.80
(-
0.
95
%)
Lupin
2,132.00
(-
1.
08
%)
Dr Reddys Laboratories
1,155.00
(-
0.
13
%)
Aurobindo Pharma
1,637.30
(-
0.
66
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar